These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 32629499)

  • 1. In Vitro Evaluation of Pro- and Anticoagulant Drugs in Children with End-Stage Liver Disease Undergoing Liver Transplantation.
    Werner MJM; Adelmeijer J; de Meijer VE; de Kleine RHJ; Scheenstra R; Bontemps STH; Reyntjens KMEM; Hulscher JBF; Porte RJ; Lisman T
    Thromb Haemost; 2020 Sep; 120(9):1240-1247. PubMed ID: 32629499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro efficacy of pro- and anticoagulant strategies in compensated and acutely ill patients with cirrhosis.
    Lisman T; Kleiss S; Patel VC; Fisher C; Adelmeijer J; Bos S; Singanayagam A; Stoy SH; Shawcross DL; Bernal W
    Liver Int; 2018 Nov; 38(11):1988-1996. PubMed ID: 29768734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis.
    Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Meijers JC; Porte RJ; Lisman T
    PLoS One; 2014; 9(2):e88390. PubMed ID: 24505487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of pro- and anticoagulant strategies in plasma of patients undergoing hepatobiliary surgery.
    Bos S; van den Boom B; Ow TW; Prachalias A; Adelmeijer J; Phoolchund A; Dunsire F; Milan Z; Roest M; Heaton N; Bernal W; Lisman T
    J Thromb Haemost; 2020 Nov; 18(11):2840-2851. PubMed ID: 33124784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma From Patients Undergoing Liver Transplantation Is Resistant to Anticoagulant Activity of Soluble Thrombomodulin.
    Burlage LC; Bos S; Adelmeijer J; Sakai T; Porte RJ; Lisman T
    Liver Transpl; 2019 Feb; 25(2):252-259. PubMed ID: 30067306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulopathy and transfusion therapy in pediatric liver transplantation.
    Nacoti M; Corbella D; Fazzi F; Rapido F; Bonanomi E
    World J Gastroenterol; 2016 Feb; 22(6):2005-23. PubMed ID: 26877606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate.
    Lindahl TL; Wallstedt M; Gustafsson KM; Persson E; Hillarp A
    Thromb Res; 2015 Mar; 135(3):544-7. PubMed ID: 25596769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
    Eerenberg ES; Kamphuisen PW; Sijpkens MK; Meijers JC; Buller HR; Levi M
    Circulation; 2011 Oct; 124(14):1573-9. PubMed ID: 21900088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation.
    Brinkman HJ; Patiwael S; Tripathi S; Meijers JC
    Thromb Res; 2016 Mar; 139():102-10. PubMed ID: 26916304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation: A Noninterventional Study.
    Tsantes AE; Kyriakou E; Ikonomidis I; Katogiannis K; Papadakis I; Douramani P; Kopterides P; Kapsimali V; Lekakis J; Tsangaris I; Bonovas S
    Medicine (Baltimore); 2016 Apr; 95(14):e3037. PubMed ID: 27057830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.
    Sciascia S; Radin M; Schreiber K; Fenoglio R; Baldovino S; Roccatello D
    Intern Emerg Med; 2017 Dec; 12(8):1101-1108. PubMed ID: 28929298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.
    Marlu R; Hodaj E; Paris A; Albaladejo P; Cracowski JL; Pernod G
    Thromb Haemost; 2012 Aug; 108(2):217-24. PubMed ID: 22627883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
    Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T
    Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban and dabigatran did not affect clotting profiles in plasma reconstituted with varying levels of autologous platelets to the same degree as heparin when evaluated using thromboelastography.
    Gantioqui J; Stevic I; Atkinson H; Chan AKC
    Blood Coagul Fibrinolysis; 2018 Sep; 29(6):521-527. PubMed ID: 29965810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemostasis in liver transplantation: Pathophysiology, monitoring, and treatment.
    Hartmann M; Szalai C; Saner FH
    World J Gastroenterol; 2016 Jan; 22(4):1541-50. PubMed ID: 26819521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives.
    Favaloro EJ; Mohammed S; Curnow J; Pasalic L
    Pathology; 2019 Apr; 51(3):292-300. PubMed ID: 30665674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of anticoagulants: an overview of current developments.
    Greinacher A; Thiele T; Selleng K
    Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of rivaroxaban, in contrast to heparin, is similar in neonatal and adult plasma.
    Novak M; Schlagenhauf A; Bernhard H; Schweintzger S; Leschnik B; Muntean W
    Blood Coagul Fibrinolysis; 2011 Oct; 22(7):588-92. PubMed ID: 21799400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
    Ragni MV
    Hematology Am Soc Hematol Educ Program; 2013; 2013():44-51. PubMed ID: 24319161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
    Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
    Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.